Beta Bionics Inc (BBNX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.50 is considered Overvalued compared with the five-year average of -10.38. The fair price of Beta Bionics Inc (BBNX) is between 6.15 to 10.61 according to relative valuation method. Compared to the current price of 12.52 USD , Beta Bionics Inc By Overvalued By 18.03%.

Relative Value

Fair Zone

6.15-10.61

Current Price：12.52

18.03%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Beta Bionics Inc (BBNX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Beta Bionics Inc (BBNX) has a current Price-to-Book (P/B) ratio of 4.37. Compared to its 3-year average P/B ratio of 2.08, the current P/B ratio is approximately 110.04% higher. Relative to its 5-year average P/B ratio of 2.08, the current P/B ratio is about 110.04% higher. Beta Bionics Inc (BBNX) has a Forward Free Cash Flow (FCF) yield of approximately -4.70%. Compared to its 3-year average FCF yield of -7.39%, the current FCF yield is approximately -36.43% lower. Relative to its 5-year average FCF yield of -7.39%, the current FCF yield is about -36.43% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BBNX competitors is 2.86, providing a benchmark for relative valuation. Beta Bionics Inc Corp (BBNX.O) exhibits a P/S ratio of 10.50, which is 266.67% above the industry average. Given its robust revenue growth of 57.15%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BBNX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BBNX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BBNX currently overvalued or undervalued?

What is Beta Bionics Inc (BBNX) fair value?

BBNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Beta Bionics Inc (BBNX) is between 6.15 to 10.61 according to relative valuation method.

How does BBNX's valuation metrics compare to the industry average?

The average P/S ratio for BBNX's competitors is 2.86, providing a benchmark for relative valuation. Beta Bionics Inc Corp (BBNX) exhibits a P/S ratio of 10.50, which is 266.67% above the industry average. Given its robust revenue growth of 57.15%, this premium appears sustainable.

What is the current P/B ratio for Beta Bionics Inc (BBNX) as of Mar 03 2026?

As of Mar 03 2026, Beta Bionics Inc (BBNX) has a P/B ratio of 4.37. This indicates that the market values BBNX at 4.37 times its book value.

What is the current FCF Yield for Beta Bionics Inc (BBNX) as of Mar 03 2026?

As of Mar 03 2026, Beta Bionics Inc (BBNX) has a FCF Yield of -4.70%. This means that for every dollar of Beta Bionics Inc's market capitalization, the company generates -4.70 cents in free cash flow.

What is the current Forward P/E ratio for Beta Bionics Inc (BBNX) as of Mar 03 2026?

As of Mar 03 2026, Beta Bionics Inc (BBNX) has a Forward P/E ratio of -18.11. This means the market is willing to pay $-18.11 for every dollar of Beta Bionics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Beta Bionics Inc (BBNX) as of Mar 03 2026?

As of Mar 03 2026, Beta Bionics Inc (BBNX) has a Forward P/S ratio of 10.50. This means the market is valuing BBNX at $10.50 for every dollar of expected revenue over the next 12 months.

BBNX Valuation